How do you counsel patients on the thrombotic risk of emicizumab in the context of multiple cardiovascular comorbidities?  

Is the arterial/venous thrombosis or TMA risk of emicizumab solely with the use of FEIBA? Do you adjust your practice at all with patients at baseline higher risk for cardiovascular events?